Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy

Bowel Preparation Clinical Trial

— PICCOLO  

Official title:

A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04113382
• Other study ID #: 000359
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: June 23, 2022
• Est. completion date: March 2026

Study information

• Verified date: December 2023
• Source: Ferring Pharmaceuticals
• Contact: Global Clinical Compliance
• Phone: +1 833-548-1402 (US/Canada)
• Email: DK0-Disclosure[@]ferring.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Bowel preparation for pediatric colonoscopy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: March 2026
• Est. primary completion date: March 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 8 Years

Eligibility

Inclusion Criteria:

• Male or female, aged 2 years to <9 years being scheduled to undergo elective colonoscopy.

• Weight =10 kg (=22 lbs).

• Participants must have had an average of three or more spontaneous bowel movements (SBM) per week for 1 month prior to the colonoscopy.

• Written informed consent (by parent(s)/ caregiver(s)/ guardian(s)) and assent (if applicable) obtained at screening.

Exclusion Criteria:

• History of significant liver, cardiovascular, or renal disease (including recent or ongoing oliguria).

• Acute surgical abdominal conditions (e.g., acute obstruction or perforation) during the screening period.

• Clinically significant abdominal pain during the screening period.

• Severe acute inflammatory bowel disease (IBD) during the screening period.

• Any prior colorectal surgery, excluding appendectomy and polyp removal.

• History of colon disease (e.g., Hirschsprung disease, volvulus, idiopathic pseudo-obstruction, or hypomotility syndrome).

• History of or ongoing intestinal ulceration, toxic megacolon or other toxic colitis.

• History of upper gastrointestinal disorder (e.g., active ulcer, pyloric stenosis or other cause of gastric retention, gastroparesis, or ileus).

• History of upper gastrointestinal surgery (e.g., gastric resection or gastric bypass), excluding cholecystectomy.

• Chronic or persistent, severe nausea or vomiting during the screening period.

• Moderate to severe dehydration during the screening period.

• Prior history of epileptic reaction, convulsions, or seizures.

• Any clinically relevant neurological events with or without association with hyponatremia during the screening period.

• Serum creatinine, estimated glomerular filtration rate (eGFR), potassium, or sodium outside normal limits during the screening period.

• Hypermagnesemia during the screening period.

• Use of the following prohibited medication: lithium (within 48 hours prior to procedure), laxatives (within 24 hours prior to procedure), drugs that in the opinion of the investigator are causing constipation in the participant (within 48 hours prior to procedure), antidiarrheal drugs (within 72 hours prior to procedure), or oral iron preparations (within 1 week prior to procedure).

• Participation in an interventional investigational trial requiring administration of an investigational drug within 30 days prior to receiving trial medication (or within 60 days for investigational drugs with an elimination half-life >15 days).

• Any clinically relevant abnormal findings in medical history, physical examination, vital signs, electrocardiogram (ECG), clinical chemistry, hematology, coagulation, or urinalysis at screening which in the opinion of the investigator(s), might put the participant at risk because of his/her participation in the trial.

• Hypersensitivity to any of the ingredients of the trial medications.

• Inability to comply with the dietary restrictions in the trial or the fluid requirements before and after investigational medicinal product (IMP) administration.

Related Conditions & MeSH terms

• Bowel Preparation

Intervention

Drug:
• CLENPIQ
CLENPIQ consists of sodium picosulfate 10.0 mg + magnesium oxide 3.5 g + citric acid, anhydrous 12.0 g. Supplied as a pre-mixed, ready-to-drink oral solution in two bottles, each containing 160 mL.
• MIRALAX
MIRALAX powder for oral solution, supplied in a 8.3 oz multi-dose bottle containing 238 g of laxative powder (polyethylene glycol [PEG] 3350).

Locations

Country	Name	City	State
United States	Ferring Investigational Site	Baltimore	Maryland
United States	The Children's Hospital at Montefiore	Bronx	New York
United States	Ferring Investigational Site	Mobile	Alabama
United States	Rady Children's Hospital	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
Ferring Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of participants classified as responders, defined by "excellent" or "good" in the Modified Aronchick scale	The efficacy of overall colon cleansing in terms of responders will be graded by a blinded endoscopist using the Modified Aronchick Scale. It is a 4-point scale that grades colon cleansing as Excellent (>90% of mucosa seen, mostly liquid stool, minimal suctioning needed for adequate visualization), Good (>90% of mucosa seen, mostly liquid stool, significant suctioning needed for adequate visualization), Fair (>90% of mucosa seen, mixture of liquid and semisolid stool, could be suctioned and/or washed) or Inadequate (<90% of mucosa seen, mixture of semisolid and solid stool which could not be suctioned or washed).The participant is considered to be a responder if overall colon cleansing is "excellent" or "good" on this 4-point scale.	On the day of colonoscopy (Day 1)
Secondary	Percentage of participants classified as "excellent" in the Modified Aronchick scale	The efficacy of overall colon cleansing in terms of responders will be graded by a blinded endoscopist using the Modified Aronchick Scale. It is a 4-point scale that grades colon cleansing as Excellent (>90% of mucosa seen, mostly liquid stool, minimal suctioning needed for adequate visualization), Good (>90% of mucosa seen, mostly liquid stool, significant suctioning needed for adequate visualization), Fair (>90% of mucosa seen, mixture of liquid and semisolid stool, could be suctioned and/or washed) or Inadequate (<90% of mucosa seen, mixture of semisolid and solid stool which could not be suctioned or washed). Percentage of participants classified as "excellent" in the Modified Aronchick scale will be reported.	On the day of colonoscopy (Day 1)
Secondary	Percentage of participants who completed the assigned dose of CLENPIQ among participants in whom nasogastric tube was not utilized to assist with CLENPIQ dosing	A nasogastric tube may be inserted if the participant is likely to fail to drink the prescribed amount of cleanout preparation within the required time. Percentage of participants who completed the assigned dose of CLENPIQ without utilizing nasogastric tube will be reported.	From randomization (Day -1) up to second dose of CLENPIQ (Day 1)
Secondary	Frequency of each category of the Modified Tolerability and Satisfaction Questionnaire: How easy was it for you/the child to drink the bowel cleanout medicine?	The tolerability and satisfaction of colon cleansing preparation for colonoscopy will be assessed by the child/ parent(s)/caregiver(s)/guardian(s) using modified tolerability and satisfaction questionnaire. The above question will be answered on a 6-point scale: (1=very easy, 2=easy, 3=okay, 4=difficult, 5=very difficult, 6=do not know).	On the day of colonoscopy (Day 1)
Secondary	Frequency of each category of the Modified Tolerability and Satisfaction Questionnaire: How did the bowel cleanout medicine taste?	The tolerability and satisfaction of colon cleansing preparation for colonoscopy will be assessed by the child/ parent(s)/caregiver(s)/guardian(s) using modified tolerability and satisfaction questionnaire. The above question will be answered on a 6-point scale: (1=very well, 2=well, 3=okay, 4=bad, 5=very bad, 6=do not know).	On the day of colonoscopy (Day 1)
Secondary	Frequency of each category of the Modified Tolerability and Satisfaction Questionnaire: How often did your/the child's tummy hurt since you/the child started the cleanout?	The tolerability and satisfaction of colon cleansing preparation for colonoscopy will be assessed by the child/parent(s)/caregiver(s)/guardian(s) using modified tolerability and satisfaction questionnaire. The above question will be answered on a 6-point scale: (1=never, 2=rarely, 3=sometimes, 4=often, 5=very often, 6=do not know).	On the day of colonoscopy (Day 1)
Secondary	Frequency of each category of the Modified Tolerability and Satisfaction Questionnaire: How often did you/the child feel fullness in your/the child's tummy since you/the child started the cleanout?	The tolerability and satisfaction of colon cleansing preparation for colonoscopy will be assessed by the child/ parent(s)/caregiver(s)/guardian(s) using modified tolerability and satisfaction questionnaire. The above question will be answered on a 6-point scale: (1=never, 2=rarely, 3=sometimes, 4=often, 5=very often, 6=do not know).	On the day of colonoscopy (Day 1)
Secondary	Frequency of each category of the Modified Tolerability and Satisfaction Questionnaire: How often did you/the child wake up last night?	The tolerability and satisfaction of colon cleansing preparation for colonoscopy will be assessed by the child/ parent(s)/caregiver(s)/guardian(s) using modified tolerability and satisfaction questionnaire. The above question will be answered on a 6-point scale: (1=never, 2=rarely, 3=sometimes, 4=often, 5=very often, 6=do not know).	On the day of colonoscopy (Day 1)
Secondary	Frequency of each category of the Modified Tolerability and Satisfaction Questionnaire: How often did you/the child feel sick to your/the child's stomach (nausea) since you/the child started the cleanout?	The tolerability and satisfaction of colon cleansing preparation for colonoscopy will be assessed by the child/ parent(s)/caregiver(s)/guardian(s) using modified tolerability and satisfaction questionnaire. The above question will be answered on a 6-point scale: (1=never, 2=rarely, 3=sometimes, 4=often, 5=very often, 6=do not know).	On the day of colonoscopy (Day 1)
Secondary	Frequency of each category of the Modified Tolerability and Satisfaction Questionnaire: How much were you/the child bothered by going to the bathroom since you/the child started the cleanout?	The tolerability and satisfaction of colon cleansing preparation for colonoscopy will be assessed by the child/parent(s)/caregiver(s)/guardian(s) using modified tolerability and satisfaction questionnaire. The above question will be answered on a 6-point scale: (1=never, 2=rarely, 3=sometimes, 4=often, 5=very often, 6=do not know).	On the day of colonoscopy (Day 1)
Secondary	Systemic concentrations of picosulfate and bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM, active metabolite of picosulfate) after randomization	For the assessment of picosulfate and BHPM concentrations, participants randomized to CLENPIQ will be further randomized (1:1 ratio) for collection of either 1 pharmacokinetic (PK) sample (PK1 subset) or 3 PK samples (PK3 subset).	For PK1 subset: 3 to 6 hours after the second dose of CLENPIQ prior to colonoscopy (Day 1); For PK3 subset: 15 minutes before, 1 to 2 hours, and 3 to 6 hours after second dose of CLENPIQ prior to colonoscopy (Day 1)
Secondary	Systemic concentrations of magnesium at screening	At screening, PK assessments of magnesium concentrations will be performed for all participants.	Screening (=21 days before scheduled colonoscopy)
Secondary	Systemic concentrations of magnesium after randomization	After randomisation, PK assessments of magnesium concentrations will be performed only for the participants randomized to CLENPIQ.	3 to 6 hours after second dose of CLENPIQ prior to colonoscopy (Day 1); 1 or 2 days after the colonoscopy (Day 2 or 3)
Secondary	Percentage of participants with adverse events (AEs)	An AE is defined as any untoward medical occurrence in a participant participating in a clinical study.; Percentage of participants with any AE (serious or non-serious) will be presented.	From screening (=21 days before scheduled colonoscopy) up to Day 28±7 after colonoscopy
Secondary	Percentage of participants with abnormal findings in vital signs	Percentage of participants with abnormal findings (clinically significant) in vital signs will be reported.	From screening (=21 days before scheduled colonoscopy) up to Day 28±7 after colonoscopy
Secondary	Percentage of participants with abnormal findings in clinical laboratory tests	Percentage of participants with abnormal findings (clinically significant) in clinical laboratory tests will be reported.	From screening (=21 days before scheduled colonoscopy) up to Day 28±7 after colonoscopy